Consensus United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:26:18 09/07/2025 BST			5-day change	1st Jan Change
299.28 ^USD	+1.65%		+1.02%	-15.47%

06-30	United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	MT
06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT

Evolution of the Average Target: United Therapeutics Corporation

Evolution of the Target Price: United Therapeutics Corporation

Changes in Analyst Recommendations: United Therapeutics Corporation

0f075edd1f6ac22e4c.sWBoB85Kp1ema4hTeO-jmcd6bCqfbwXQMRDmkP9oCUo.5QJdQKYAwCTNG-wBLJX6rY9XHh7lOmToe3qxxpYqcAHaLQ9NlHLTAPUnzQ~e7cc117540172da87e94e89f7008fcc3

Analysts' recommendations: United Therapeutics Corporation

UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	06-30	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating	03-18	MT
UBS Adjusts Price Target on United Therapeutics to $460 From $475, Keeps Buy Rating	02-06	MT
BofA Adjusts Price Target on United Therapeutics to $328 From $327	02-03	MT
UBS Raises Price Target on United Therapeutics to $475 From $415, Keeps Buy Rating	01-08	MT
Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating	28/08/24	MT
UBS Adjusts Price Target on United Therapeutics to $365 From $370, Maintains Buy Rating	01/08/24	MT
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target	01/08/24	MT
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating	25/07/24	MT
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating	11/07/24	MT
Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310	11/07/24	MT
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating	08/07/24	MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing	28/06/24	MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing	14/06/24	MT
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating	12/06/24	MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing	16/05/24	MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing	14/05/24	MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	10/05/24	MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing	07/05/24	MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing	06/05/24	MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing	06/05/24	MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	03/05/24	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	02/05/24	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Ecart obj. / dr
UNITED THERAPEUTICS CORPORATION		+28.6%
ELI LILLY AND COMPANY		+22.42%
JOHNSON & JOHNSON		+8.62%
ABBVIE INC.		+10.2%
NOVO NORDISK A/S		+43.3%
ROCHE HOLDING AG		+16.95%
NOVARTIS AG	-	-1.87%
ASTRAZENECA PLC		+31.12%
MERCK & CO., INC.		+25.09%
AMGEN INC.		+5.81%
Average		+19.02%
Weighted average by Cap.		+18.83%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

294.42USD

Average target price

378.63USD

Spread / Average Target

+28.60%

High Price Target

510.00USD

Spread / Highest target

+73.22%

Low Price Target

314.00USD

Spread / Lowest Target

+6.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Cantor Fitzgerald
BofA Securities
Wells Fargo Securities
Oppenheimer
Goldman Sachs
Leerink Partners
Wedbush
Morgan Stanley
Ladenburg Thalmann
Argus
Credit Suisse
HC Wainwright
Jefferies & Co.
JPMorgan Chase
BTIG
J.P. Morgan Chase